Novel Ab-Targeted Therapeutic Strategies For Alzheimer?s Disease | 12480
Journal of Alzheimers Disease & Parkinsonism
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
A? accumulation is critical to the development of Alzheimer?s disease (AD). Current efforts at reducing A? 40 or 42 have
focused on modulating ?-secretase to produce shorter A?, while attempting to spare other secretase functions. Earlier
attempts at lowering total A? were unsatisfactory as they targeted the catalytic activities of ?- or ?-secretase, enzymes known
to also hydrolyze other substrates. New therapeutic approaches that can inhibit total A? without altering secretase activity are
therefore of great interest. Here we demonstrate such a new, different and early approach for the treatment of AD. We previous
showed that an interaction between APP and Presenilin (PS) in cell cultures is a required initial step in the ultimate production
of A? from APP. Furthermore, if the entire NH2-terminal domain of the PS was first added to the culture, the amount of A?
produced was significantly reduced. We exploited the potential therapeutic significance of these results to inquire whether
isolated small soluble peptides within the NH2-terminal domain of PS-1 retained enough of the inhibitory activity of the whole
domain, such that when added to model systems of AD, they effectively reduced A? production. Here we demonstrate that two
small, non-over-lapping water-soluble peptides, P4 and P8 can substantially and specifically inhibit A? production in vitro and
in the brains of APP transgenic mice. These peptide-induced reductions of total A? (and of A? 40 and 42) did not alter ?- or
?-secretase activities. P4 and P8 offer new and effective potential drug candidates for the treatment of AD.
Nazneen Dewji is an Associate Professor at the University of California, San Diego. She was born in Tanzania and raised in England. She earned her
B.Sc. (Hons.) in Biochemistry in 1978 and her Ph.D. in 1982 at the University of London. In 1986 she joined the department of Medicine at UCSD,
where she began working on Alzheimer's disease (AD). The discoveries made in her laboratory support the development of new drug discovery
targets for the treatment of AD. In 2006 she founded a company, Cenna Biosciences Inc., to further develop novel candidates for the treatment of AD.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals